Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
AbstractBackground:. Digital mammography has replaced film mammography in breast-screening programs globally, including Australia. This led to an increase in the rate of detection, but whether…
The James Cancer and Aging Resiliency (CARE) clinic is a leader in treating older cancer patients. Patients have been treated with blood and bone marrow…
Getting around MD Anderson doesn’t have to be overwhelming. We’re here to help you navigate your appointments. #Houston #Hospital #MDAnderson #MDAndersonCanc…
The FDA has approved one of the first HPV self-collection solutions, which can be used to identify women who are at risk of developing cervical…
This case-based feature focused on oncologists at 2 virtual events who examined the development of new EGFR-targeted therapies including combinations of amivantamab with lazertinib and…
Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology and an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer…
FHD-286 reduced chromatin accessibility, repressed c-Myc and PU.1, and diminished leukemia-initiating potential in AML stem/progenitor cells.FHD-286 combin
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Navigate the evolving paradigms in advanced ovarian cancer care. Delve into the latest treatments and methodologies improving patient outcomes.